Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Roughly one in three preteens and teens ages 12 to 17 in the United States had prediabetes in 2023, according to new data ...

The "try and fail" language is flawed when weight loss is used as the primary measure of success with lifestyle interventions ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing ...

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several life-threatening illnesses.

A new study shows that using tirzepatide together with menopause hormone therapy can lead to greater weight loss in postmenopausal women who are overweight or have obesity. These findings were shared ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

Tirzepatide may confer larger increases in testosterone levels among men with metabolic hypogonadism than testosterone ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.

New research from investigators at Mass General Brigham suggests that a commonly used type 2 diabetes medication is linked to ...